Compare TSQ & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSQ | CRDL |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.8M | 97.3M |
| IPO Year | 2000 | N/A |
| Metric | TSQ | CRDL |
|---|---|---|
| Price | $5.34 | $1.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $12.50 | $9.00 |
| AVG Volume (30 Days) | 85.0K | ★ 688.9K |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | ★ 15.07% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $438,695,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.59 | N/A |
| P/E Ratio | $4.65 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.30 | $0.77 |
| 52 Week High | $10.39 | $1.59 |
| Indicator | TSQ | CRDL |
|---|---|---|
| Relative Strength Index (RSI) | 51.95 | 56.61 |
| Support Level | $4.75 | $0.88 |
| Resistance Level | $4.98 | $1.12 |
| Average True Range (ATR) | 0.22 | 0.08 |
| MACD | 0.11 | 0.02 |
| Stochastic Oscillator | 89.00 | 85.71 |
Townsquare Media Inc is a radio, digital media, entertainment, and digital marketing solutions company principally focused on being the premier local advertising and marketing solutions platform in small and mid-sized markets across the United States. It has three segments which are Subscription Digital Marketing Solutions, Digital Advertising, and Broadcast Advertising. It earns the majority of the revenue from the Broadcasting Advertising segment, which includes its local, regional, and national advertising products and solutions delivered via terrestrial radio broadcast. Its portfolio includes local media brands such as WYRK.com, WJON.com, and NJ101.5.com, and premier national music brands such as XXLmag.com, TasteofCountry.com, UltimateClassicRock.com, and Loudwire.com.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.